Amylyx Pharmaceuticals Prices Upsized $500M Public Offering to Support Pipeline Growth

Cambridge, MA, August 19, 2026 (Business Wire) -- Amylyx Pharmaceuticals has priced an upsized public offering expected to generate approximately $500 million in gross proceeds. The company plans to use the capital to support development of its clinical-stage programs and broader corporate activities. The financing significantly strengthens Amylyx’s balance sheet as it advances its pipeline toward upcoming clinical milestones.

Read full article here.